CBIZ Reports Third-Quarter and Nine Months Ended September 30, 2026 Financial
CBIZ Reports Third-Quarter and Nine Months Ended September 30, 2026 Financial Results Third-Quarter Financial Highlights:
CLEVELAND (October 19, 2026) – CBIZ, Inc., (NYSE: CBZ) (“CBIZ” or the “Company”), a leading national professional services advisor, today announced results for the third quarter and nine months ended September 30, 2026. Proposed Transaction with Grant Thornton and New Mountain As previously disclosed, CBIZ and an affiliate of Grant Thornton in the U.S. (“Grant Thornton”), backed by New Mountain Capital, announced on July 29, 2026 that they entered into a definitive merger agreement pursuant to which Grant Thornton will acquire CBIZ in an all- cashtransaction with an enterprise value of $5.0 billion, or $55.00 per share (the “proposed transaction”). The proposed transaction is expected to close in the fourth quarter of 2026, subject to approval by CBIZ shareholders, receipt of required regulatory approvals, and satisfaction of other customary closing conditions. Following the completion of the proposed transaction, CBIZ’s common stock will no longer be listed on the New York Stock Exchange, and CBIZ will become a private company. Full Year Financial Outlook and Conference Call Information Due to the proposed transaction and as previously disclosed, the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss third quarter results. Page 1 NYSE: CBZ • www.CBIZ.com
CBIZ, Inc. (NYSE: CBZ) is a leading professional services advisor to middle market businesses nationwide. With industry knowledge and expertise in accounting, tax, advisory, benefits, insurance, and technology, CBIZ delivers actionable insights to help clients anticipate what is next and discover new ways to accelerate growth. CBIZ has more than 9,500 team members across 23 major markets coast to coast. For more information, visit www.cbiz.com.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact included in this release, including, without limitation, statements about the proposed transaction, our financial position, business strategy, plans and objectives for future performance, are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are commonly identified by the use of such terms and phrases as “will,” “could,” “can,” “may,” “strive,” “hope,” “intend,” “believe,” “estimate,” “continue,” “plan,” “expect,” “project,” “anticipate,” “outlook,” “foreseeable future,” “seek” and words or phrases of similar import in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated services, sales efforts, expenses, and financial results.
From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Any or all of our forward-looking statements in this release and in any other public statements that we make are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to: that one or more closing conditions to the proposed transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, or that the required approval by the shareholders of CBIZ may not be obtained; the risk that the proposed transaction may not be completed on the terms or in the time frame expected by CBIZ and Grant Thornton, or at all; unexpected costs, charges or expenses resulting from the proposed transaction; uncertainty of the expected financial performance and results of operations of the combined company following completion of the proposed transaction; failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of CBIZ and Grant Thornton, on the expected timeframe or at all; the ability of the combined company to implement its business strategy; difficulties and delays in the combined company achieving revenue and cost synergies; inability of the combined company to retain and hire key personnel; the occurrence of any event that could give rise to termination of the proposed transaction; the risk that shareholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or completion of the proposed transaction or result in significant costs of defense, indemnification and liability; evolving legal, regulatory and tax regimes; changes in general economic, competitive, technological and/or industry-specific conditions affecting the businesses and industries in which CBIZ and Grant Thornton operate; actions by third parties, including government agencies and ratings agencies, relating to the proposed transaction; risks that any debt financing anticipated in connection with the proposed transaction is not obtained or that such financing cannot be obtained on the anticipated timing or terms or unexpected costs or expenses in connection therewith; risks related to the disruption of management time from ongoing business operations due to the
pendency of the proposed transaction, or other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, partners, or other counterparties; risks that any announcements relating to the proposed transaction could have adverse effects on the market price of CBIZ’s common stock, credit ratings, or operating results, and may have an adverse effect on the ability of CBIZ to retain and hire key personnel, retain customers, and maintain relationships with business partners, suppliers and customers; the risk that the market price of CBIZ’s common stock may decline if the proposed transaction is not completed; our ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including ability to remediate our material weaknesses in our internal control over financial reporting; payments on accounts receivable may be slower than expected, or amounts due on receivables or notes may not be fully collectible; our business could be adversely affected if the non-attest business assets we acquired, or the attest assets CBIZ CPAs P.C. acquired, from Marcum LLP (“Marcum”) do not perform to our expectations or we underestimate the liabilities we have assumed; we are dependent on the services of our executive officers, and other key employees, the loss of any of whom may have a material adverse effect on our business, financial condition and results of operations; our profitability could suffer if we are not able to effectively utilize our employees, maintain operational efficiencies or manage our cost structure; restrictions imposed by independence requirements and conflict of interest rules, as well as the nature and terms of our current administrative service agreements, limit our ability to provide services to clients of the attest firms with which we have contractual relationships and the ability of such attest firms to provide attestation services to our clients; our goodwill and other intangible assets could become impaired, which could lead to material non-cash charges against earnings and a material impact on our results of operations and financial condition; certain liabilities resulting from acquisitions are estimated and could lead to a material impact on our results of operations; we may fail to realize the anticipated benefits of acquisitions, or they may prove disruptive and could result in the combined business failing to meet our expectations; claims or adverse publicity could harm our brand, reputation and ability to compete and attract and retain clients, talent and future acquisition targets; we may not be able to acquire and finance additional businesses, which could limit our ability to pursue our business strategy; we will incur transaction, integration, and restructuring costs in connection with our acquisition program; governmental regulations and interpretations are subject to changes, which could have a material adverse effect on our financial condition; uncertainty in the current economic and geopolitical environment could lead to declines in demand for certain of our services; changes in the United States healthcare environment, including new healthcare legislation, may adversely affect the revenue and margins in our healthcare benefit business; we are subject to risks relating to processing customer transactions for our payroll and other transaction processing businesses; cyberattacks or other security breaches involving our computer systems or the systems of one or more of our vendors could materially and adversely affect our business; we are subject to risk as it relates to software that we license from third parties; we are reliant on information processing systems and any failure or disruptions of these systems could have a material adverse effect on our business, financial condition and results of operations; we could be held liable for errors and omissions; the business services industry is competitive and fragmented, if we are unable to compete effectively, our business, financial condition and results of operations could be negatively impacted; failure to maintain our reputation and brand could impact our ability to attract and retain clients, employees and future acquisition targets, and may have a material adverse effect on our business, financial condition and results of operations; we are dependent on our existing client base and our ability to retain and expand our relationships with those clients; our clients may terminate our engagements with little or no notice and without penalty, which may result in unexpected declines in our revenue or unexpected costs; given our levels of share-based compensation, our tax rate may vary significantly depending on our stock price; we may be subject to the actions of activist stockholders; rapid technological changes could significantly impact our competitive position, client
relationships and operating results and our ability to realize the anticipated benefits of our acquisition of the non-attest business assets and liabilities of Marcum and CBIZ CPAs P.C.’s purchase of substantially all of Marcum’s attest business assets (the “Marcum Transaction”); the widespread outbreak of a communicable illness or any other public health crisis could adversely affect our business, financial condition and results of operations; we require a significant amount of cash for interest payments on our debt and to expand our business as planned; terms of our amended and restated credit agreement providing for $2.0 billion in senior secured credit facilities, consisting of a $1.4 billion term loan and $600 million revolving credit facility, could adversely affect our ability to run our business and/or reduce stockholder returns; our failure to satisfy covenants in our debt instruments could cause a default under those instruments; our increased leverage following the Marcum Transaction may adversely impact our business; we may be more sensitive to revenue fluctuations than other companies, which could result in fluctuations in the market price of our common stock; the significant number of shares issuable as the stock consideration in the Marcum Transaction may adversely impact our stock price; the future issuance of additional shares could adversely affect the price of our common stock; and there is volatility in our stock price.
Such forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Should one or more of these risks materialize, or should the underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, projected or implied. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially. All forward looking statements made in this release are made only as of the date hereof, and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are advised, however, to consult any further disclosures we make on related subjects in the current, quarterly, periodic and annual reports we file with the Securities and Exchange Commission. Also note that we provide a cautionary discussion of the risks, uncertainties and possibly inaccurate assumptions relevant to our businesses in “Item 1. Business” and “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as amended. These are factors that we think could cause our actual results to differ materially from expected and historical results. Other factors besides those described here could also adversely affect our operating or financial performance.
To supplement our consolidated financial statements, which are prepared and presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), we also present Adjusted Net Income (Loss), Adjusted Diluted Earnings Per Share (“EPS”), Adjusted EBITDA, Adjusted EBITDA Margin and Free Cash Flow, which are non-GAAP measures. These non-GAAP measures are adjusted to exclude the impact of the Marcum Transaction, integration costs, amortization of acquired intangible assets, and other significant non-operating related gains and losses management does not consider ongoing in nature. The presentation of non-GAAP financial information is designed to supplement the Company’s financial information presented in accordance with GAAP, is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision-making, and to evaluate results relative to employee compensation targets. We believe that these non-GAAP financial measures provide meaningful supplemental information to stockholders, debt holders, and other interested parties in assessing our performance. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance by excluding significant acquisition expenses, certain one-time non-recurring items, and gains and losses that management does not consider ongoing in nature. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater
transparency with respect to key measures used by management in its financial and operational decision-making and (2) they are used by our stockholders and analyst community to determine the health of our business. These non-GAAP measures may not be comparable to similar non-GAAP measures presented by other companies. The presentation of such non- GAAP measures, which may include exclusions of non-recurring items, should not be construed as an inference that the Company’s future results will be unaffected by other non-recurring items. Management provides specific information regarding the GAAP amounts excluded from or included in these non-GAAP financial measures. Additionally, management provides reconciliations of these non-GAAP financial measures to their most comparable financial measures presented in accordance with GAAP. Please see the schedules captioned “GAAP Reconciliation” at the end of this release for additional information and the applicable reconciliations.
Investor Relations: Chris Sikora, VP, Investor Relations & Corporate Finance, [email protected]
Media: Amy McGahan, Director of Corporate & Strategic Communications, [email protected]
CBIZ, INC. FINANCIAL HIGHLIGHTS (UNAUDITED) THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (In thousands, except percentages and per share data)
We sponsor a Non-qualified Deferred Compensation Plan (the “deferred compensation plan”), under which a CBIZ employee’s compensation deferral is held in a rabbi trust and invested accordingly as directed by the employee. The activities related to the deferred compensation plan are recorded in “Corporate and Other” for segment reporting purposes. Gains and losses resulting from the adjustments to the fair value of the invested (1) assets in the deferred compensation plan are recorded as an increase or decrease to the “Other income (expense), net”, directly offset by the same adjustments as an increase or decrease to compensation expense (recorded as “Operating expense” or “Corporate general and administrative expense”) in the accompanying Unaudited Condensed Consolidated Statements of Comprehensive Income. The deferred compensation plan has no impact on “Income before income tax expense” or diluted earnings per share.
Income and expenses related to the deferred compensation plan for the three months ended September 30, 2026, and 2025, are as follows (in thousands, except percentages):
Excluding the impact of the above-mentioned income and expenses related to the deferred compensation plan, the operating results for the three months ended September 30, 2026, and 2025, are as follows (in thousands, except percentages):
Included in “Other income, net” for the three months ended September 30, 2026, and 2025, is (2) income of $1.1 million and expense of $0.5 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ’s prior acquisitions.
Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted EBITDA to the most directly comparable (3) GAAP financial measures at the end of this release, and for additional information as to the usefulness of the non-GAAP financial measures to stockholders and investors, see “Non-GAAP Financial Measures”.
CBIZ, INC. FINANCIAL HIGHLIGHTS (UNAUDITED) NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (In thousands, except percentages and per share data)
We sponsor a Non-qualified Deferred Compensation Plan (the “deferred compensation plan”), under which a CBIZ employee’s compensation deferral is held in a rabbi trust and invested accordingly as directed by the employee. The activities related to the deferred compensation plan are recorded in “Corporate and Other” for segment reporting purposes. Gains and losses resulting from the adjustments to the fair value of the invested (1) assets in the deferred compensation plan are recorded as an increase or decrease to the “Other income (expense), net”, directly offset by the same adjustments as an increase or decrease to compensation expense (recorded as “Operating expense” or “Corporate general and administrative expense”) in the accompanying Unaudited Condensed Consolidated Statements of Comprehensive Income. The deferred compensation plan has no impact on “Income before income tax expense” or diluted earnings per share.
Income and expenses related to the deferred compensation plan for the nine months ended September 30, 2026, and 2025, are as follows (in thousands, except percentages):
Excluding the impact of the above-mentioned income and expenses related to the deferred compensation plan, the operating results for the nine months ended September 30, 2026, and 2025, are as follows (in thousands, except percentages):
Included in “Other income, net” for the nine months ended September 30, 2026, and 2025, is (2) income of $2.6 million and expense of $2.0 million, respectively, related to net changes in the fair value of contingent consideration related to CBIZ’s prior acquisitions.
Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted EBITDA to the most directly comparable (3) GAAP financial measures at the end of this release and for additional information as to the usefulness of the non-GAAP financial measures to stockholders and investors see “Non-GAAP Financial Measures”.
During the nine months ended September 30, 2026, the National Practice group was combined with the Financial Service practice group to better align with internal (1) management and reporting structure. As a result, the Financial Services revenue and gross margin for the three and nine months ended September 30, 2025 was adjusted to reflect this change.
Represents operating expenses not directly allocated to individual businesses, including stock-based compensation, consolidation and integration charges, and certain advertising expenses. “Operating expenses - unallocated” also includes gains or losses attributable to the assets held in a rabbi trust associated with the Company’s deferred compensation plan. These gains or losses do not impact “Income (2) before income tax expense” as they are directly offset by the same adjustment to “Other income (expense), net” in the Consolidated Statements of Comprehensive Income. Net gains or losses recognized from adjustments to the fair value of the assets held in the rabbi trust are recorded as compensation expense (income) in “Operating expenses” and “Corporate, general and administrative expenses,” and offset in “Other income (expense), net.”
Nine Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 218,627 $ 194,861 Adjustments to reconcile net income to net cash provided by operating activities: Gain on sale of — (1,124 ) operations, net of tax Depreciation and 70,411 74,313 amortization expense Bad debt expense, net of 5,072 3,216 recoveries Adjustment to contingent purchase price (2,638 ) 1,984 liabilities Stock-based compensation 22,158 19,572 expense Deferred income taxes 22,939 8,815 Other, net 5,477 5,256 Changes in assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net (231,285 ) (186,884 ) Other assets (8,771 ) (31,071 ) Accounts payable (8,835 ) 9,162 Income taxes payable 45,465 46,364 Accrued personnel costs (14,389 ) (33,962 ) Other liabilities 22,824 (61,656 ) Net cash provided by operating 147,055 48,846 activities Net cash used in (29,303 ) (16,913 ) investing activities Net cash used in (185,915 ) (75,233 ) financing activities Net decrease in cash, cash equivalents (68,163 ) (43,300 ) and restricted cash Cash, cash equivalents and restricted 218,090 187,170 cash at beginning of year Cash, cash equivalents and restricted $ 149,927 $ 143,870 cash at end of period Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet: Cash and cash $ 17,551 $ 16,969 equivalents Restricted cash 40,853 44,455 Cash equivalents included in funds held 91,523 82,446 for clients Total cash, cash equivalents and $ 149,927 $ 143,870 restricted cash
This table reconciles Free Cash Flow to the most directly comparable GAAP financial measure of net cash provided by operating activities. Free Cash Flow is a non-GAAP measure (1) that management believes provides a more complete understanding of the factors and trends affecting our cash flows. This information is useful to investors, as it offers a measure of cash generated from our business that can be used for our strategic business objectives.
CBIZ, INC. SELECT FINANCIAL DATA AND RATIOS (UNAUDITED) (In thousands, except percentages, DSO, and per share data)
Reflects the gross debt for the Term Loan and Revolving Credit Facility (1) excluding the associated unamortized deferred debt issuance costs totaling $13.8 million and $16.5 million, respectively, as of September 30, 2026 and December 31, 2025.
CBIZ, INC. GAAP RECONCILIATION Net Income (Loss) and Diluted Earnings Per Share (“EPS”) to Adjusted Net Income (Loss), Adjusted Diluted EPS, Adjusted EBITDA, and Adjusted EBITDA Margin (1) (Unaudited. Amounts in thousands, except per share data)
This table reconciles Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and Adjusted EBITDA margin to the most directly comparable GAAP financial measures. Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and (1) Adjusted EBITDA margin exclude the impact of the Marcum Transaction and other significant non-operating related gains and losses that management does not consider on-going in nature. Please refer to the ‘Non-GAAP Financial Measures’ section for further management discussion.
These costs include, but are not limited to, certain consulting, (2) technology, personnel, as well as other integration costs related to the Marcum Transaction.
(3) These costs included unusual and one-time legal and professional services costs associated with the Company’s pending transaction.
Stock-based compensation expense reported for the three months ended September 30, 2026 and 2025 excluded (4) $3.1 million and $3.4 million, respectively, of stock-based compensation expense reported as “Integration costs related to acquisitions” above.
During the three months ended September 30, 2025, the Company recorded (5) a $0.3 million adjustment to the accrued legal costs associated with the $12.5 million legal settlement when payments were made.
(6) Represents amounts relating to the impact of the previously disclosed ESPP correction.
Depreciation expense reported for the three months ended September 30, 2026 and 2025 excluded $16 thousand and $0.2 million, respectively, of depreciation expense (7) reported as “Integration costs related to acquisitions” above. The accelerated depreciation was associated with certain technology assets from the Marcum Transaction.
CBIZ, INC. GAAP RECONCILIATION Net Income (Loss) and Diluted Earnings Per Share (“EPS”) to Adjusted Net Income (Loss), Adjusted Diluted EPS and Adjusted EBITDA (1) (Unaudited. Amounts in thousands, except per share data)
This table reconciles Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and Adjusted EBITDA margin to the most directly comparable GAAP financial measures. Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and (1) Adjusted EBITDA margin exclude the impact of the Marcum Transaction and other significant non-operating related gains and losses that management does not consider on-going in nature. Please refer to the ‘Non-GAAP Financial Measures’ section for further management discussion.
These costs include, but are not limited to, certain consulting, (2) technology, personnel, as well as other integration costs related to the Marcum Transaction.
Gain related the finalization of working capital and related purchase (3) price adjustments associated with the Marcum Transaction.
(4) These costs included unusual and one-time legal and professional services costs associated with the Company’s pending transaction.
During the nine months ended September 30, 2026, the Company recorded an estimated loss of $7.2 million associated with a legal matter which the Company plans to settle. During the nine months ended September 30, 2025, the Company recorded a gain of $12.5 million related to a legal settlement payment from a small group of (5) former employees. The settlement loss and gain were recorded in “other income (expense), net” on the consolidated statement of comprehensive income. The costs associated with this litigation were $1.1 million for the nine months ended September 30, 2025 and were recorded in “Corporate general and administrative expenses” on the consolidated statement of comprehensive income.
Stock-based compensation expense reported for the nine months ended September 30, 2026 and 2025 excluded (6) $9.4 million and $6.7 million, respectively, of stock-based compensation expense reported as “Integration costs related to acquisitions” above.
(7) Represents amounts relating to the impact of the previously disclosed ESPP correction.
Depreciation expense reported for the nine months ended September 30, 2026 and 2025 excluded $48 thousand and $1.8 million, respectively, of depreciation expense (8) reported as “Integration costs related to acquisitions” above. The accelerated depreciation was associated with certain technology assets from the Marcum Transaction.
Full text with the tables
Exhibit 99.1
FOR IMMEDIATE RELEASE
CBIZ Reports Third-Quarter and Nine Months Ended September 30, 2026 Financial
Results Third-Quarter Financial Highlights:
• Total revenue of $702M, up 1.2%; Financial Services revenue up 1.2%
• Net income of $47M, up 56.7%; GAAP EPS of $0.79, up 64.6%
• Adjusted EBITDA of $132M, up 6.3%; Adjusted diluted EPS of $1.21, up
14.2%
Nine Months Ended September 30, 2026 Financial Highlights:
• Total revenue of $2,233M, up 0.8%; Financial Services revenue up 1.1%
• Net income of $219M, up 12.2%; GAAP EPS of $3.62, up 18.3%
• Adjusted EBITDA of $479M, down 1.2%; Adjusted diluted EPS of $4.64, up
5.9%
• Operating cash flow up $98M; Free cash flow up $91M
CLEVELAND (October 19, 2026) – CBIZ, Inc., (NYSE: CBZ) (“CBIZ” or the
“Company”), a leading national professional services advisor, today announced
results for the third quarter and nine months ended September 30, 2026. Proposed
Transaction with Grant Thornton and New Mountain As previously disclosed, CBIZ
and an affiliate of Grant Thornton in the U.S. (“Grant Thornton”), backed by New
Mountain Capital, announced on July 29, 2026 that they entered into a definitive
merger agreement pursuant to which Grant Thornton will acquire CBIZ in an all-
cashtransaction with an enterprise value of $5.0 billion, or $55.00 per share
(the “proposed transaction”). The proposed transaction is expected to close in
the fourth quarter of 2026, subject to approval by CBIZ shareholders, receipt of
required regulatory approvals, and satisfaction of other customary closing
conditions. Following the completion of the proposed transaction, CBIZ’s common
stock will no longer be listed on the New York Stock Exchange, and CBIZ will
become a private company. Full Year Financial Outlook and Conference Call
Information Due to the proposed transaction and as previously disclosed, the
Company will not be providing financial guidance for the full year 2026 or
hosting a conference call to discuss third quarter results. Page 1 NYSE: CBZ •
www.CBIZ.com
About CBIZ
CBIZ, Inc. (NYSE: CBZ) is a leading professional services advisor to middle
market businesses nationwide. With industry knowledge and expertise in
accounting,
tax, advisory, benefits, insurance, and technology, CBIZ delivers actionable
insights to help clients anticipate what is next and discover new ways to
accelerate growth. CBIZ has more than 9,500 team members across 23 major markets
coast to coast.
For more information, visit www.cbiz.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, as amended (the
“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). All statements other than statements of historical
fact included in this release, including, without limitation,
statements about the proposed transaction, our financial position, business
strategy, plans and objectives for future performance, are forward-looking
statements. You can identify these statements by the fact that they do not
relate strictly to
historical or current facts. Forward-looking statements are commonly identified
by the use of such terms and phrases as “will,” “could,” “can,” “may,” “strive,”
“hope,”
“intend,” “believe,” “estimate,” “continue,” “plan,” “expect,” “project,”
“anticipate,” “outlook,” “foreseeable future,”
“seek” and words or phrases of similar import in connection with any discussion
of future operating or financial performance. In particular, these include
statements relating to future actions, future performance or results of current
and anticipated services, sales efforts, expenses, and financial results.
From time to time, we may also provide oral or written forward-looking
statements in other materials we release to the public. Any or all of our
forward-looking statements in this release and in any other public statements
that we make are subject to certain risks and uncertainties that could cause
actual results to
differ materially from those projected. Such risks and uncertainties include,
but are not limited to: that one or more closing conditions to the proposed
transaction, including certain regulatory approvals, may not be satisfied or
waived, on a
timely basis or otherwise, or that the required approval by the shareholders of
CBIZ may not be obtained; the risk that the proposed transaction may not be
completed on the terms or in the time frame expected by CBIZ and Grant Thornton,
or at all;
unexpected costs, charges or expenses resulting from the proposed transaction;
uncertainty of the expected financial performance and results of operations of
the combined company following completion of the proposed transaction; failure
to realize
the anticipated benefits of the proposed transaction, including as a result of
delay in completing the proposed transaction or integrating the businesses of
CBIZ and Grant Thornton, on the expected timeframe or at all; the ability of the
combined
company to implement its business strategy; difficulties and delays in the
combined company achieving revenue and cost synergies; inability of the combined
company to retain and hire key personnel; the occurrence of any event that could
give rise to
termination of the proposed transaction; the risk that shareholder litigation in
connection with the proposed transaction or other litigation, settlements or
investigations may affect the timing or completion of the proposed transaction
or result in
significant costs of defense, indemnification and liability; evolving legal,
regulatory and tax regimes; changes in general economic, competitive,
technological and/or industry-specific conditions affecting the businesses and
industries in which
CBIZ and Grant Thornton operate; actions by third parties, including government
agencies and ratings agencies, relating to the proposed transaction; risks that
any debt financing anticipated in connection with the proposed transaction is
not
obtained or that such financing cannot be obtained on the anticipated timing or
terms or unexpected costs or expenses in connection therewith; risks related to
the disruption of management time from ongoing business operations due to the
Page 2
NYSE: CBZ • www.CBIZ.com
pendency of the proposed transaction, or other effects of the pendency of the
proposed transaction on the relationship of any of the parties to the
transaction with their employees, customers,
partners, or other counterparties; risks that any announcements relating to the
proposed transaction could have adverse effects on the market price of CBIZ’s
common stock, credit ratings, or operating results, and may have an adverse
effect on
the ability of CBIZ to retain and hire key personnel, retain customers, and
maintain relationships with business partners, suppliers and customers; the risk
that the market price of CBIZ’s common stock may decline if the proposed
transaction
is not completed; our ability to maintain effective internal control over
financial reporting and disclosure controls and procedures, including ability to
remediate our material weaknesses in our internal control over financial
reporting; payments
on accounts receivable may be slower than expected, or amounts due on
receivables or notes may not be fully collectible; our business could be
adversely affected if the non-attest business assets we acquired,
or the attest assets CBIZ CPAs P.C. acquired, from Marcum LLP (“Marcum”) do not
perform to our expectations or we underestimate the liabilities we have assumed;
we are dependent on the services of our executive officers, and other key
employees, the loss of any of whom may have a material adverse effect on our
business, financial condition and results of operations; our profitability could
suffer if we are not able to effectively utilize our employees, maintain
operational
efficiencies or manage our cost structure; restrictions imposed by independence
requirements and conflict of interest rules, as well as the nature and terms of
our current administrative service agreements, limit our ability to provide
services to
clients of the attest firms with which we have contractual relationships and the
ability of such attest firms to provide attestation services to our clients; our
goodwill and other intangible assets could become impaired, which could lead to
material non-cash charges against earnings and a material impact on our results
of operations and financial condition; certain liabilities resulting from
acquisitions are estimated and could lead to a material
impact on our results of operations; we may fail to realize the anticipated
benefits of acquisitions, or they may prove disruptive and could result in the
combined business failing to meet our expectations; claims or adverse publicity
could harm our
brand, reputation and ability to compete and attract and retain clients, talent
and future acquisition targets; we may not be able to acquire and finance
additional businesses, which could limit our ability to pursue our business
strategy; we will
incur transaction, integration, and restructuring costs in connection with our
acquisition program; governmental regulations and interpretations are subject to
changes, which could have a material adverse effect on our financial condition;
uncertainty in the current economic and geopolitical environment could lead to
declines in demand for certain of our services; changes in the United States
healthcare environment, including new healthcare legislation, may adversely
affect the
revenue and margins in our healthcare benefit business; we are subject to risks
relating to processing customer transactions for our payroll and other
transaction processing businesses; cyberattacks or other security breaches
involving our computer
systems or the systems of one or more of our vendors could materially and
adversely affect our business; we are subject to risk as it relates to software
that we license from third parties; we are reliant on information processing
systems and any
failure or disruptions of these systems could have a material adverse effect on
our business, financial condition and results of operations; we could be held
liable for errors and omissions; the business services industry is competitive
and
fragmented, if we are unable to compete effectively, our business, financial
condition and results of operations could be negatively impacted; failure to
maintain our reputation and brand could impact our ability to attract and retain
clients,
employees and future acquisition targets, and may have a material adverse effect
on our business, financial condition and results of operations; we are dependent
on our existing client base and our ability to retain and expand our
relationships with
those clients; our clients may terminate our engagements with little or no
notice and without penalty, which may result in unexpected declines in our
revenue or unexpected costs; given our levels of share-based compensation, our
tax rate may vary
significantly depending on our stock price; we may be subject to the actions of
activist stockholders; rapid technological changes could significantly impact
our competitive position, client
Page 3
NYSE: CBZ • www.CBIZ.com
relationships and operating results and our ability to realize the anticipated
benefits of our acquisition of the non-attest business assets and
liabilities of Marcum and CBIZ CPAs P.C.’s purchase of substantially all of
Marcum’s attest business assets (the “Marcum Transaction”); the widespread
outbreak of a communicable illness or any other public health crisis could
adversely affect our business, financial condition and results of operations; we
require a significant amount of cash for interest payments on our debt and to
expand our business as planned; terms of our amended and restated credit
agreement
providing for $2.0 billion in senior secured credit facilities, consisting of a
$1.4 billion term loan and $600 million revolving credit facility, could
adversely affect our ability to run our business and/or reduce stockholder
returns; our failure to satisfy covenants in our debt instruments could cause a
default under those instruments; our increased leverage following the Marcum
Transaction may adversely impact our business; we may be more sensitive to
revenue
fluctuations than other companies, which could result in fluctuations in the
market price of our common stock; the significant number of shares issuable as
the stock consideration in the Marcum Transaction may adversely impact our stock
price; the
future issuance of additional shares could adversely affect the price of our
common stock; and there is volatility in our stock price.
Such
forward-looking statements can be affected by inaccurate assumptions we might
make or by known or unknown risks and uncertainties. Should one or more of these
risks materialize, or should the underlying assumptions prove incorrect, actual
results
may vary materially from those anticipated, estimated, projected or implied.
Consequently, no forward-looking statement can be guaranteed. Our actual future
results may vary materially. All forward looking statements made in this release
are made
only as of the date hereof, and we undertake no obligation to publicly update
any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. You are advised, however, to
consult any
further disclosures we make on related subjects in the current, quarterly,
periodic and annual reports we file with the Securities and Exchange Commission.
Also note that we provide a cautionary discussion of the risks, uncertainties
and possibly
inaccurate assumptions relevant to our businesses in “Item 1. Business” and
“Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2025, as
amended. These are factors that we think could cause our actual results to
differ materially from expected and historical results. Other factors besides
those described here could also adversely affect our operating or financial
performance.
Non-GAAPFinancial Measures
To supplement our consolidated financial statements, which are prepared and
presented in accordance with United States Generally Accepted Accounting
Principles
(“GAAP”), we also present Adjusted Net Income (Loss), Adjusted Diluted Earnings
Per Share (“EPS”), Adjusted EBITDA, Adjusted EBITDA Margin and Free Cash Flow,
which are non-GAAP
measures. These non-GAAP measures are adjusted to exclude the impact of the
Marcum Transaction, integration costs, amortization of acquired intangible
assets, and other significant non-operating related gains and losses management
does not consider ongoing in nature. The presentation of non-GAAP financial
information is designed to supplement the
Company’s financial information presented in accordance with GAAP, is not
intended to be considered in isolation or as a substitute for, or superior to,
the financial information prepared and presented in accordance with GAAP. We use
these non-GAAP financial measures for financial and operational decision-making,
and to evaluate results relative to employee compensation targets. We believe
that these non-GAAP
financial measures provide meaningful supplemental information to stockholders,
debt holders, and other interested parties in assessing our performance. These
non-GAAP financial measures also facilitate
management’s internal comparisons to our historical performance by excluding
significant acquisition expenses, certain one-time non-recurring items, and
gains and
losses that management does not consider ongoing in nature. We believe these
non-GAAP financial measures are useful to investors both because (1) they allow
for greater
Page 4
NYSE: CBZ • www.CBIZ.com
transparency with respect to key measures used by management in its financial
and operational decision-making and (2) they are used by our stockholders and
analyst community to determine the
health of our business. These non-GAAP measures may not be comparable to similar
non-GAAP measures presented by other companies. The presentation of such non-
GAAP measures, which may include exclusions of non-recurring items, should not
be construed as an inference that the Company’s future results will be
unaffected by
other non-recurring items. Management provides specific information regarding
the GAAP amounts excluded from or included in these non-GAAP financial measures.
Additionally, management provides reconciliations of these non-GAAP financial
measures to their most comparable financial measures presented in accordance
with GAAP. Please see the schedules captioned
“GAAP Reconciliation” at the end of this release for additional information and
the applicable reconciliations.
Contact:
Investor Relations: Chris Sikora, VP, Investor Relations & Corporate Finance,
[email protected]
Media: Amy McGahan, Director of Corporate & Strategic Communications,
[email protected]
CBIZ, Inc., Cleveland, Ohio, (216) 447-9000
Page 5
NYSE: CBZ • www.CBIZ.com
CBIZ, INC. FINANCIAL HIGHLIGHTS (UNAUDITED) THREE MONTHS ENDED SEPTEMBER 30,
2026 AND 2025 (In thousands, except percentages and per share data)
Three
Months
Ended
Septemb…
30, 2026 % 2025 %
──────────────────────────────────────────────────────────────────────────────
Revenue $ 702,240 100.0 % $ 693,818 100.0 %
Operat…
expens… 588,186 83.8 603,689 87.0
(1)
Gross 114,054 16.2 90,129 13.0
margin
Corpor…
general
and 23,877 3.4 31,265 4.5
admini…
expens…
(1)
Operat… 90,177 12.8 58,864 8.5
income
Other
(expen…
income:
Intere… (23,986 ) (3.4 ) (27,960 ) (4.0 )
expense
Gain
from
acquis… — — 1,124 0.2
related
adjust…
net
Other
income, 1,449 0.2 8,378 1.2
net (1)
(2)
Total
other (22,537 ) (3.2 ) (18,458 ) (2.6 )
expens…
net
Income
before
income 67,640 9.6 40,406 5.9
tax
expense
Income
tax 20,404 10,260
expense
Net $ 47,236 6.7 % $ 30,146 4.3 %
income
Diluted
income
per
share:
Diluted
earnin… $ 0.79 $ 0.48
per
share
Diluted
weight…
average 59,986 62,699
common
shares
outsta…
Other
data:
Adjust…
EBITDA $ 131,852 18.8 % $ 124,005 17.9 %
(3)
Adjust…
Diluted $ 1.21 $ 1.06
EPS (3)
We sponsor a Non-qualified Deferred Compensation Plan (the
“deferred compensation plan”), under which a CBIZ employee’s
compensation deferral is held in a rabbi trust and invested accordingly
as directed by the employee. The activities related to the deferred
compensation plan are recorded
in “Corporate and Other” for segment reporting purposes. Gains and
losses resulting from the adjustments to the fair value of the invested
(1) assets in the deferred compensation plan are recorded as an increase or
decrease to the
“Other income (expense), net”, directly offset by the same adjustments
as an increase or decrease to compensation expense (recorded as
“Operating expense” or “Corporate general and administrative expense”)
in the
accompanying Unaudited Condensed Consolidated Statements of
Comprehensive Income. The deferred compensation plan has no impact on
“Income before income tax expense” or diluted earnings per share.
Income and expenses related to the deferred compensation plan for the three
months ended September 30, 2026, and 2025, are as follows (in thousands, except
percentages):
Three
Months
Inco… Ended
stat… Septe…
line 30, % of % of
item… 2026 Reven… 2025 Reve…
──────────────────────────────────────────────────────────────────────────────
Oper… $ (566 ) (0.1 )% $ 7,847 1.1 %
expe…
Corp…
gene…
& (191 ) — 1,076 0.2 %
admi…
expe…
Other
inco… (757 ) (0.1 )% 8,923 1.3 %
net
Page 6 NYSE: CBZ • www.CBIZ.com
Excluding the impact of the above-mentioned income and expenses related to the
deferred compensation plan, the operating results for the three months ended
September 30, 2026, and 2025, are as follows (in thousands, except percentages):
…
…
…
…
…
… … % … …
… … … … …
… … … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ … ) $ … … % $ … $ … $ …
… … ) … … % … … …
… … … … % … … ) ) …
… — … … % … — …
Included in “Other income, net” for the three months ended September
30, 2026, and 2025, is
(2) income of $1.1 million and expense of $0.5 million, respectively,
related to net changes in the fair value of contingent consideration
related to CBIZ’s prior acquisitions.
Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted
EBITDA to the most directly comparable
(3) GAAP financial measures at the end of this release, and for additional
information as to the usefulness of the non-GAAP financial measures to
stockholders and investors, see
“Non-GAAP Financial Measures”.
CBIZ, INC. FINANCIAL HIGHLIGHTS (UNAUDITED) NINE MONTHS ENDED SEPTEMBER 30, 2026
AND 2025 (In thousands, except percentages and per share data)
Nine
Months
Ended
Septemb…
30, 2026 % 2025 %
──────────────────────────────────────────────────────────────────────────────
Reven… $ 2,233,… 100.0 % $ 2,215,3… 100.0 %
Opera…
expen… 1,820,… 81.5 1,809,1… 81.7
(1)
Gross 412,509 18.5 406,140 18.3
margin
Corpo…
gener…
and 103,754 4.6 86,972 3.9
admin…
expen…
(1)
Opera… 308,755 13.9 319,168 14.4
income
Other
(expe…
incom…
Inter… (72,237 ) (3.2 ) (80,983 ) (3.7 )
expen…
Gain
from
acqui… 57,955 2.6 1,124 0.1
relat…
adjus…
net
Other
incom…
net 11,382 0.5 31,786 1.4
(1)
(2)
Total
other
income (2,900 ) (0.1 ) (48,073 ) (2.2 )
(expe…
net
Income
before
income 305,855 13.7 271,095 12.2
tax
expen…
Income
tax 87,228 76,234
expen…
Net 218,627 9.8 % 194,861 8.8 %
income
Dilut…
earni… $ 3.62 $ 3.06
per
share
Dilut…
weigh…
avera… 60,333 63,609
common
shares
outst…
Other
data:
Adjus…
EBITDA $ 479,345 21.5 % $ 485,127 21.9 %
(3)
Adjus…
Dilut… $ 4.64 $ 4.38
EPS
(3)
Page 7 NYSE: CBZ • www.CBIZ.com
We sponsor a Non-qualified Deferred Compensation Plan (the
“deferred compensation plan”), under which a CBIZ employee’s
compensation deferral is held in a rabbi trust and invested accordingly
as directed by the employee. The activities related to the deferred
compensation plan are recorded
in “Corporate and Other” for segment reporting purposes. Gains and
losses resulting from the adjustments to the fair value of the invested
(1) assets in the deferred compensation plan are recorded as an increase or
decrease to the
“Other income (expense), net”, directly offset by the same adjustments
as an increase or decrease to compensation expense (recorded as
“Operating expense” or “Corporate general and administrative expense”)
in the
accompanying Unaudited Condensed Consolidated Statements of
Comprehensive Income. The deferred compensation plan has no impact on
“Income before income tax expense” or diluted earnings per share.
Income and expenses related to the deferred compensation plan for the nine
months ended September 30, 2026, and 2025, are as follows (in thousands, except
percentages):
Nine
Income Months
statem… Ended
line Septem… % of % of
items: 30, 2026 Reven… 2025 Revenue
──────────────────────────────────────────────────────────────────────────────
Opera… $ 13,478 0.6 % $ 17,132 0.8 %
expen…
Corpo…
gener…
and 1,788 0.1 % 2,415 0.1 %
admin…
income
Other
incom… 15,266 0.7 % 19,547 0.9 %
net
Excluding the impact of the above-mentioned income and expenses related to the
deferred compensation plan, the operating results for the nine months ended
September 30, 2026, and 2025, are as follows (in thousands, except percentages):
…
…
…
…
…
… … % … …
… … … … …
… … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … … % $ … $ … … …
… … … … % … … … …
… … ) … ) … … … … ) … …
… — … … % … — … …
Included in “Other income, net” for the nine months ended September 30,
2026, and 2025, is
(2) income of $2.6 million and expense of $2.0 million, respectively,
related to net changes in the fair value of contingent consideration
related to CBIZ’s prior acquisitions.
Refer to the schedules reconciling Adjusted Diluted EPS and Adjusted
EBITDA to the most directly comparable
(3) GAAP financial measures at the end of this release and for additional
information as to the usefulness of the non-GAAP financial measures to
stockholders and investors see
“Non-GAAP Financial Measures”.
Page 8 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. FINANCIAL HIGHLIGHTS (UNAUDITED) SELECT SEGMENT DATA (In thousands)
Three Nine
Mont… Mon…
Ended End…
Sept… Sep…
30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Fin… $ 597,… $ 590,… $ 1,91… $ 1,8…
Ser…
Ben…
and 104,… 103,… 314,… 318…
Ins…
Ser…
Tot… $ 702,… $ 693,… $ 2,23… $ 2,2…
Rev…
Gro…
Mar…
Fin… $ 109,… $ 95,9… $ 400,… $ 386…
Ser…
Ben…
and 18,2… 19,3… 56,9… 64,…
Ins…
Ser…
Ope…
exp…
-
una…
(2):
Oth… $ (14,… ) $ (17,… ) $ (30,… ) $ (28… )
exp…
Def… 566 (7,8… ) (13,… ) (17… )
com…
Tot…
Gro… $ 114,… $ 90,1… $ 412,… $ 406…
Mar…
As a
% of 16.2 % 13.0 % 18.5 % 18.3 %
Rev…
During the nine months ended September 30, 2026, the National Practice
group was combined with the
Financial Service practice group to better align with internal
(1) management and reporting structure. As a result, the Financial Services
revenue and gross margin for the three and nine months ended September
30, 2025 was adjusted to reflect this
change.
Represents operating expenses not directly allocated to individual
businesses, including stock-based
compensation, consolidation and integration charges, and certain
advertising expenses. “Operating expenses - unallocated” also includes
gains or losses attributable to the assets held in a rabbi trust
associated with the Company’s
deferred compensation plan. These gains or losses do not impact “Income
(2) before income tax expense” as they are directly offset by the same
adjustment to “Other income (expense), net” in the Consolidated
Statements of
Comprehensive Income. Net gains or losses recognized from adjustments
to the fair value of the assets held in the rabbi trust are recorded as
compensation expense (income) in “Operating expenses” and “Corporate,
general and
administrative expenses,” and offset in “Other income (expense), net.”
Page 9 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. SELECT CASH FLOW DATA (UNAUDITED) (In thousands)
Nine Months Ended
September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 218,627 $ 194,861
Adjustments to reconcile
net income to
net cash provided by
operating
activities:
Gain on sale of — (1,124 )
operations, net of tax
Depreciation and 70,411 74,313
amortization expense
Bad debt expense, net of 5,072 3,216
recoveries
Adjustment to contingent
purchase price (2,638 ) 1,984
liabilities
Stock-based compensation 22,158 19,572
expense
Deferred income taxes 22,939 8,815
Other, net 5,477 5,256
Changes in assets and
liabilities, net
of acquisitions and
divestitures:
Accounts receivable, net (231,285 ) (186,884 )
Other assets (8,771 ) (31,071 )
Accounts payable (8,835 ) 9,162
Income taxes payable 45,465 46,364
Accrued personnel costs (14,389 ) (33,962 )
Other liabilities 22,824 (61,656 )
Net cash provided by
operating 147,055 48,846
activities
Net cash used in (29,303 ) (16,913 )
investing activities
Net cash used in (185,915 ) (75,233 )
financing activities
Net decrease in cash,
cash equivalents (68,163 ) (43,300 )
and restricted cash
Cash, cash equivalents
and restricted 218,090 187,170
cash at beginning of
year
Cash, cash equivalents
and restricted $ 149,927 $ 143,870
cash at end of period
Reconciliation of cash,
cash equivalents and
restricted cash to the
consolidated
balance sheet:
Cash and cash $ 17,551 $ 16,969
equivalents
Restricted cash 40,853 44,455
Cash equivalents
included in funds held 91,523 82,446
for clients
Total cash, cash
equivalents and $ 149,927 $ 143,870
restricted cash
Page 10 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. GAAP RECONCILIATION Operating Cash Flow to Free Cash Flow (1)
(Unaudited. Amounts in thousands, except per share data)
Nine Months Ended
September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net cash provided by
operating $ 147,055 $ 48,846
activities
Less:
Additions to property and (21,820 ) (15,035 )
equipment
Free Cash Flow $ 125,235 $ 33,811
This table reconciles Free Cash Flow to the most directly comparable
GAAP financial measure of net cash
provided by operating activities. Free Cash Flow is a non-GAAP measure
(1) that management believes provides a more complete understanding of the
factors and trends affecting our cash flows. This information is
useful to investors, as it offers a measure of cash generated from our
business that can be used for our strategic business objectives.
Page 11 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. SELECT FINANCIAL DATA AND RATIOS (UNAUDITED) (In thousands, except
percentages, DSO, and per share data)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 17,551 $ 18,290
Restricted cash 40,853 38,234
Accounts receivable, net 782,392 555,995
Other current assets 88,389 79,693
Current assets before funds
held for $ 929,185 $ 692,212
clients
Funds held for clients 134,454 207,037
Goodwill and other intangible
assets, 2,828,643 2,869,790
net
Total assets $ 4,610,429 $ 4,409,528
Current liabilities before
client fund 468,227 $ 462,484
obligations, excluding
short-term debt
Client fund obligations 135,305 206,738
Current portion, Term Loan (1) $ 96,250 $ 70,000
Revolver Facility (1) 176,500 142,400
Long-term portion, Term Loan(1) 1,181,250 1,260,000
Total liabilities $ 2,697,705 $ 2,647,461
Treasury stock (1,156,495 ) (1,078,521 )
Total stockholders’ equity $ 1,912,724 $ 1,762,067
Debt to equity 66.8 % 75.5 %
Shares outstanding 54,761 54,380
Basic weighted average common
shares 60,057 62,909
outstanding
Diluted weighted average common
shares 60,333 63,240
outstanding
Reflects the gross debt for the Term Loan and Revolving Credit Facility
(1) excluding the associated unamortized
deferred debt issuance costs totaling $13.8 million and $16.5 million,
respectively, as of September 30, 2026 and December 31, 2025.
Page 12 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. GAAP RECONCILIATION Net Income (Loss) and Diluted Earnings Per Share
(“EPS”) to Adjusted Net Income (Loss), Adjusted Diluted EPS, Adjusted EBITDA,
and Adjusted EBITDA Margin (1) (Unaudited. Amounts in thousands, except per
share data)
Th…
Mo…
En…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Be… Co…
Fi… and & Co… EPS
Se… In… Ot…
Se…
N…
i… $ 11… $ 18… $ (8… ) $ 47… $ 0…
(…
A…
A…
of
a… 17… 1,… — 18… 0…
i…
a…
I…
c…
r… 1,… 1 16… 17… 0…
to
a…
(…
C…
p… 110 190 1,… 2,… 0…
r…
c…
S… 944 — 2,… 3,… 0…
c…
E…
c… — — (5… ) (5… ) (… )
i…
(…
I…
t…
e… — — (1… ) (1… ) (… )
r…
to
a…
A…
n… $ 12… $ 19… $ (7… ) $ 72… $ 1…
i…
(…
I… — — 23… 23…
e…
I…
t… — — 20… 20…
e…
T…
e…
r…
to — — 10… 10…
t…
a…
a…
D… 3,… 491 1,… 5,…
(…
A… $ 13… $ 20… $ (2… ) $ 13…
E…
As
a
% 22… % 19… % N/A 18… %
of
R…
Th…
Mo…
En…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Be… Co…
Fi… and & Co… EPS
Se… In… Ot…
Se…
N…
i… $ 96… $ 19… $ (8… ) $ 30… $ 0…
(…
A…
A…
of
a… 17… 1,… — 18… 0…
i…
a…
I…
c…
r… 10… 228 18… 28… 0…
to
a…
(…
L…
s…
a… — — (2… ) (2… ) —
r…
c…
S… — — 3,… 3,… 0…
c…
G…
on
s… (1… ) — — (1… ) (… )
of
o…
n…
I…
t…
e… — — (1… ) (1… ) (… )
r…
to
a…
A…
n… $ 12… $ 21… $ (7… ) $ 67… $ 1…
i…
(…
I… — — 27… 27…
e…
I…
t… — — 10… 10…
e…
T…
e…
r…
to — — 12… 12…
t…
a…
a…
D… 4,… 525 1,… 5,…
A… $ 12… $ 21… $ (2… ) $ 12…
E…
As
a
% 21… % 21… % N/A 17… %
of
R…
Page 13 NYSE: CBZ • www.CBIZ.com
This table reconciles Adjusted net income (loss), Adjusted diluted EPS,
Adjusted EBITDA, and Adjusted EBITDA
margin to the most directly comparable GAAP financial measures.
Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and
(1) Adjusted EBITDA margin exclude the impact of the Marcum Transaction and
other significant non-operating related gains and losses that
management does not consider on-going in nature. Please refer to the
‘Non-GAAP
Financial Measures’ section for further management discussion.
These costs include, but are not limited to, certain consulting,
(2) technology, personnel, as well as other
integration costs related to the Marcum Transaction.
(3) These costs included unusual and one-time legal and professional
services costs associated with the Company’s pending transaction.
Stock-based compensation expense reported for the three months ended
September 30, 2026 and 2025 excluded
(4) $3.1 million and $3.4 million, respectively, of stock-based
compensation expense reported as “Integration costs related to
acquisitions” above.
During the three months ended September 30, 2025, the Company recorded
(5) a $0.3 million adjustment to
the accrued legal costs associated with the $12.5 million legal
settlement when payments were made.
(6) Represents amounts relating to the impact of the previously disclosed
ESPP correction.
Depreciation expense reported for the three months ended September 30,
2026 and 2025 excluded
$16 thousand and $0.2 million, respectively, of depreciation expense
(7) reported as “Integration costs related to acquisitions” above. The
accelerated depreciation was associated with certain technology assets
from the Marcum
Transaction.
Page 14 NYSE: CBZ • www.CBIZ.com
CBIZ, INC. GAAP RECONCILIATION Net Income (Loss) and Diluted Earnings Per Share
(“EPS”) to Adjusted Net Income (Loss), Adjusted Diluted EPS and Adjusted EBITDA
(1) (Unaudited. Amounts in thousands, except per share data)
Ni…
mo…
en…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Be… Co…
Fi… and & Co… EPS
Se… In… Ot…
Se…
N…
i… $ 39… $ 57… $ (2… ) $ 21… $ 3…
(…
A…
I…
c…
r… 21… 24 34… 55… 0…
to
a…
(…
A…
of
a… 51… 3,… — 55… 0…
i…
a…
G…
f…
a… — — (5… ) (5… ) (… )
r…
a…
n…
C…
p… 110 190 5,… 5,… 0…
r…
c…
L…
s…
a… 7,… 7,… 0…
r…
c…
S… 2,… — 10… 12… 0…
c…
E…
c… — — 7,… 7,… 0…
e…
(…
I…
t…
e… — — (2… ) (2… ) (… )
r…
to
a…
A…
n… $ 47… $ 61… $ (2… ) $ 28… $ 4…
i…
(…
I… — — 72… 72…
e…
I…
t… — — 87… 87…
e…
T…
e…
r…
to — — 24… 24…
t…
a…
a…
D… 9,… 1,… 4,… 15…
(…
A… $ 48… $ 63… $ (6… ) $ 47…
E…
As
a
% 25… % 20… % N/A 21… %
of
R…
Ni…
mo…
en…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Be… Co…
Fi… and & Co… EPS
Se… In… Ot…
Se…
N…
i… $ 38… $ 65… $ (2… ) $ 19… $ 3…
(…
A…
I…
c…
r… 17… 609 45… 63… 1…
to
a…
(…
A…
of
a… 51… 5,… — 56… 0…
i…
a…
L…
s…
a… — — (1… ) (1… ) (… )
r…
c…
S… — — 9,… 9,… 0…
c…
G…
on
s… (1… ) — — (1… ) (… )
of
o…
n…
I…
t…
e… — — (3… ) (3… ) (… )
r…
to
a…
A…
n… $ 45… $ 71… $ (2… ) $ 27… $ 4…
i…
(…
I… — — 80… 80…
e…
I…
t… — — 76… 76…
e…
T…
e…
r…
to — — 32… 32…
t…
a…
a…
D… 11… 1,… 3,… 16…
A… $ 46… $ 72… $ (5… ) $ 48…
E…
As
a
% 24… % 22… % N/A 21… %
of
R…
Page 15 NYSE: CBZ • www.CBIZ.com
This table reconciles Adjusted net income (loss), Adjusted diluted EPS,
Adjusted EBITDA, and Adjusted EBITDA
margin to the most directly comparable GAAP financial measures.
Adjusted net income (loss), Adjusted diluted EPS, Adjusted EBITDA, and
(1) Adjusted EBITDA margin exclude the impact of the Marcum Transaction and
other significant non-operating related gains and losses that
management does not consider on-going in nature. Please refer to the
‘Non-GAAP
Financial Measures’ section for further management discussion.
These costs include, but are not limited to, certain consulting,
(2) technology, personnel, as well as other
integration costs related to the Marcum Transaction.
Gain related the finalization of working capital and related purchase
(3) price adjustments associated with the
Marcum Transaction.
(4) These costs included unusual and one-time legal and professional
services costs associated with the Company’s pending transaction.
During the nine months ended September 30, 2026, the Company recorded
an estimated loss of
$7.2 million associated with a legal matter which the Company plans to
settle. During the nine months ended September 30, 2025, the Company
recorded a gain of $12.5 million related to a legal settlement payment
from a small group of
(5) former employees. The settlement loss and gain were recorded in “other
income (expense), net” on the consolidated statement of comprehensive
income. The costs associated with this litigation were $1.1 million for
the nine months
ended September 30, 2025 and were recorded in “Corporate general and
administrative expenses” on the consolidated statement of comprehensive
income.
Stock-based compensation expense reported for the nine months ended
September 30, 2026 and 2025 excluded
(6) $9.4 million and $6.7 million, respectively, of stock-based
compensation expense reported as “Integration costs related to
acquisitions” above.
(7) Represents amounts relating to the impact of the previously disclosed
ESPP correction.
Depreciation expense reported for the nine months ended September 30,
2026 and 2025 excluded
$48 thousand and $1.8 million, respectively, of depreciation expense
(8) reported as “Integration costs related to acquisitions” above. The
accelerated depreciation was associated with certain technology assets
from the Marcum
Transaction.
Page 16 NYSE: CBZ • www.CBIZ.com